#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Raynaud's phenomenon Squamous cell carcinoma of the oral cavity Adrenocortical carcinoma Lymphoma Renal cancer metastatic Neuropathic arthropathy Congenital nephrogenic diabetes insipidus Demyelination Cutaneous lupus erythematosus Acquired ATTR amyloidosis Familial haemophagocytic lymphohistiocytosis Retinopathy proliferative Cystic fibrosis respiratory infection suppression Ocular lymphoma Solitary fibrous tumour More trials…

    Learn about Rare Diseases

    Familial amyotrophic lateral sclerosis – Basic Information Mantle cell lymphoma Burkitt’s lymphoma Immunodeficiency congenital – Basic Information Richter’s syndrome – Life with Disease KBG syndrome – Trials in Disease Haemophagocytic lymphohistiocytosis – Treatment Wiskott-Aldrich syndrome – Diagnostics Congenital nephrogenic diabetes insipidus – Treatment Langerhans cell sarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK5460025A LTG-001 Insulin Lispro Omp10 Autologous Chondrocytes Atropine Sulfate Monohydrate Bgb-15025 Citrate Enomimeran Belatacept CAL101 ALKYLATING AGENTS Water For Injection Clemastine Tedizolid Phosphate Ataluren Piflufolastat (18F) Metamizole Sodium Monohydrate Odm-212 Romosozumab Capsaicin More therapies…

    Learn about Your Condition

    Cardiac failure chronic Cytokine release syndrome Endometrial cancer stage II Pyelonephritis acute Persistent depressive disorder Lung cancer metastatic Encephalitis Japanese B Rhabdomyosarcoma Malignant melanoma Osteomyelitis acute Dementia Alzheimer's type Laryngeal cancer stage III Left ventricular failure Amyloidosis Follicular lymphoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Factor IX deficiency

  • Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Factor IX deficiency
    • Factor VIII deficiency
    Investigated Drugs:
    • Efmoroctocog Alfa
    • Eftrenonacog Alfa
    Bulgaria Croatia Czechia France Hungary Ireland +4

  • Title: Study of gene therapy Etranacogene Dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Factor IX deficiency
    Investigated Drugs:
    • Etranacogene Dezaparvovec
    Belgium Denmark Germany Ireland The Netherlands Sweden

  • Long-term Safety Study of Etranacogene Dezaparvovec in Adult Men with Hemophilia B

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Factor IX deficiency
    Investigated Drugs:
    • Etranacogene Dezaparvovec
    Belgium Denmark Germany Ireland The Netherlands Sweden

  • Study on Long-Term Safety and Efficacy of Etranacogene Dezaparvovec for Adults with Severe or Moderately Severe Hemophilia B

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Factor IX deficiency
    Investigated Drugs:
    • Etranacogene Dezaparvovec
    Germany The Netherlands

  • Study on the Efficacy and Safety of Fidanacogene Elaparvovec Gene Therapy in Adult Males with Moderate to Severe Hemophilia B

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Factor IX deficiency
    Investigated Drugs:
    • Fidanacogene Elaparvovec
    Belgium France Germany Greece Italy Spain +1

  • Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Factor IX deficiency
    • Factor VIII deficiency
    Investigated Drugs:
    • Concizumab
    Denmark Estonia France Germany Hungary Italy +5
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!